At the news
? NEUTRALIMPACT 2/10 144 filed Oct 30, 2026 at 16:20 ET
Director Michael S. Brown filed a Form 144 notice of intent to sell 1,929 shares of Regeneron common stock, with an approximate market value of $1.58 million based on the filing date. The shares were acquired through stock option exercises, and the sale is planned for execution on October 30, 2026.
- Reporting person: Michael S. Brown, a Director of Regeneron Pharmaceuticals, Inc.
- Proposed sale of 1,929 shares of common stock.
- Estimated aggregate market value: $1,579,407.33.
- Shares acquired via exercise of stock options on October 30, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access